# Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial

> **NCT07650240** · PHASE2 · RECRUITING · sponsor: **Mayo Clinic** · enrollment: 202 (estimated)

## Conditions studied

- Recurrent Prostate Adenocarcinoma
- Stage IVB Prostate Cancer AJCC v8
- Castration-Sensitive Prostate Cancer
- Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
- Prostate Cancer
- Prostate Adenocarcinoma
- Adenocarcinoma of the Prostate
- Localized Prostate Carcinoma
- Metastatic Prostate Cancer
- Metastatic Prostate Adenocarcinoma
- Advanced Prostate Cancer
- Advanced Prostate Adenocarcinoma

## Interventions

- **DRUG:** Abiraterone Acetate
- **PROCEDURE:** Biospecimen Collection
- **DRUG:** Leuprolide Acetate
- **DRUG:** Lutetium Lu 177 Vipivotide Tetraxetan
- **DRUG:** Prednisone
- **PROCEDURE:** PSMA PET-CT Scan
- **OTHER:** Quality-of-Life Assessment
- **PROCEDURE:** Single Photon Emission Computed Tomography

## Key facts

- **NCT ID:** NCT07650240
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-08-04
- **Primary completion:** 2030-12-30
- **Final completion:** 2030-12-30
- **Target enrollment:** 202 (ESTIMATED)
- **Last updated:** 2026-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07650240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07650240, "Study of PSMA-targeted Therapy and Androgen Receptor Suppression in Low-volume Metastatic ProstatE Cancer: SPARKLE Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07650240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*